Your session is about to expire
← Back to Search
LY3022855 + BRAF/MEK Inhibitors for Melanoma
Study Summary
This trial is studying a combination of targeted therapies to see if they are effective in treating advanced melanoma that has a BRAF V600E or BRAF V600K genetic mutation.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 1 trial • 72 Patients • NCT02718911Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have not fully recovered from side effects of previous cancer treatment.You have previously been treated with a BRAF or MEK inhibitor.Your heart's pumping function (LVEF) must be at least 50%.You have a confirmed diagnosis of melanoma with specific gene mutations, and you have not been treated with certain medications before.If you want to join the second part of the study, you need to have a way for the doctors to measure the disease.You are able to perform daily activities without any major issues or with some minor limitations.Your organs and bone marrow must be working normally.You are taking certain medications that can interact with the study drug.You need to have a sample of your tumor tissue from a previous test.You have had allergic reactions to similar drugs as LY3022855, vemurafenib, or cobimetinib.You have been diagnosed with HIV.You or someone in your family has a history of long QT syndrome.You are taking strong or moderate CYP3A inducer medications.You have a problem with your eyes found during an eye exam.You cannot swallow or keep down pills.You have brain tumors that have not been treated yet.You have had another type of cancer in the past.You have a stomach or intestinal condition that could affect how your body absorbs vemurafenib and cobimetinib.You have advanced melanoma with a specific genetic mutation, and standard treatments are not working for you.Participants joining the first part of the trial must have a way for doctors to measure their disease.Your heart's electrical activity, measured on a heart test, should be below a certain number.
- Group 1: LY3022855 + Vemurafenib + Cobimetinib
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedent studies that have employed LY3022855?
"Currently, there are 75 investigations for the efficacy of LY3022855 with 4 studies in the final phase. Most trials involving this drug occur in Shizuoka and New South Wales but it is available at over two thousand sites globally."
What is the primary application of LY3022855 as a therapeutic agent?
"Patients suffering from metastatic melanoma, non-small cell lung carcinoma, or unresectable melanoma can benefit from LY3022855 as a form of treatment."
Is there still an opportunity for participants to join this experiment?
"Clinicaltrials.gov reveals that this medical trial is not presently recruiting participants, despite having been originally posted on June 6th 2017 and recently updated July 26th 2022. Fortunately, there are 829 other studies currently enrolling patients."
How many participants are enrolled in this research venture?
"Unfortunately, this medical trial is no longer recruiting. It was initially posted on 6th June 2017 and last updated on 26 July 2022. If you are still looking for studies related to melanoma, there are currently 754 active trials enrolling patients with that condition, as well as 75 specifically for LY3022855."
Share this study with friends
Copy Link
Messenger